Avantor
Avantor, Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$6.6B
Operating marginCalculated
-3.8%
Net assets to total assetsCalculated
47.2%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-3.8%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-3.0%
Capital efficiency
★☆☆☆☆position among all companies
-9.5%
Revenue and profit
Performance, financial position and capital allocation
Avantor
Recent performance trends
Avantor
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$7.4 billion | US$7.5 billion | US$7.0 billion | US$6.8 billion | US$6.6 billion |
| Operating income | US$1.0 billion | US$1.1 billion | US$0.7 billion | US$1.1 billion | US$-0.2 billion |
| Net income | US$0.6 billion | US$0.7 billion | US$0.3 billion | US$0.7 billion | US$-0.5 billion |
| Total assets | US$13.9 billion | US$13.5 billion | US$13.0 billion | US$12.1 billion | US$11.8 billion |
| Shareholders' equity | US$4.2 billion | US$4.9 billion | US$5.3 billion | US$6.0 billion | US$5.6 billion |
| Net cash provided by (used in) operating activities | US$1.0 billion | US$0.8 billion | US$0.9 billion | US$0.8 billion | US$0.6 billion |
| Net cash provided by (used in) investing activities | US$-4.1 billion | US$-0.1 billion | US$-0.1 billion | US$0.4 billion | US$-0.1 billion |
| Net cash provided by (used in) financing activities | US$3.2 billion | US$-0.6 billion | US$-0.8 billion | US$-1.3 billion | US$-0.4 billion |
| Cash and cash equivalents | US$0.3 billion | US$0.4 billion | US$0.3 billion | US$0.3 billion | US$0.4 billion |
Revenue scale in the same industry
Avantor
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 17 companies
- 21 CoherentFY Jun 2026 US$7.1B
- 22 Agilent TechnologiesFY Oct 2025 US$6.9B
- 23 AvantorThis companyFY Dec 2025 US$6.6B
- 24 Teledyne TechnologiesFY Dec 2025 US$6.1B
- 25 Edwards LifesciencesFY Dec 2025 US$6.1B
- … 18 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.6 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.4 billion | Consolidated | Disclosed |
| Net assets | US$5.6 billion | Consolidated | Disclosed |
| Net sales | US$6.6 billion | Consolidated | Disclosed |
| Operating income | US$-0.2 billion | Consolidated | Disclosed |
| Net income | US$-0.5 billion | Consolidated | Disclosed |
| Total assets | US$11.8 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$75.10 million | Consolidated | Disclosed |
| Operating margin | -3.8% | Consolidated | Calculated |
| Net assets to total assets | 47.2% | Consolidated | Calculated |
| Net margin | -8.1% | Consolidated | Calculated |
| Return on equity | -9.5% | Consolidated | Calculated |